Is Selinisol (Silvio) a targeted drug or a chemotherapy drug?

Selinexor (Selinexor), trade name XPOVIO, is a targeted drug rather than a traditional chemotherapy drug. It is an oral selective inhibitor of nuclear export (SINE) that works primarily by inhibiting the nuclear export protein XPO1 (also known as Exportin 1). Unlike traditional chemotherapy drugs, targeted drugs are designed to precisely target specific molecular pathways or proteins to interfere with the growth and survival of cancer cells.

XPO1 is a key nuclear export protein responsible for the transport of many tumor suppressor proteins (such as p53, RB1, and FOXOs) from the nucleus to the cytoplasm. Cancer cells usually overexpress XPO1 to reduce the accumulation of these inhibitory proteins in the nucleus, thereby evading apoptosis. Selinesol (Silvio)By selectively inhibiting XPO1, these tumor suppressor proteins accumulate in the nucleus and activate the apoptosis pathway, thereby inhibiting the growth and proliferation of cancer cells.

Compared with traditional chemotherapy drugs, targeted drugs such as Selinisol (Silvio) have the following advantages:

1.More selective: Targeted drugs specifically act on specific molecules or pathways, reducing damage to normal cells, thereby reducing the incidence of side effects.

2.More effective: By targeting the specific weaknesses of cancer cells, targeted drugs can significantly inhibit the growth and spread of tumors in many cases.

3.Resistance management: Although cancer cells may become resistant to targeted drugs, the progression-free survival of patients can be effectively prolonged by combining different targeted drugs or using them in conjunction with other treatments.

Seleniso (Silvio) has been approved by the U.S. Food and Drug Administration (FDA) approved for the treatment of multiple myeloma and relapsed /refractory diffuse large B cell lymphoma (DLBCL). It has shown significant anticancer activity in clinical trials, particularly in patients who have developed resistance to multiple conventional treatments.

AlthoughSelinesol (Silvio)has shown significant efficacy, its use is also associated with some adverse reactions, such as nausea, decreased appetite, fatigue, weight loss, thrombocytopenia, and hyponatremia. These side effects need to be closely monitored and managed during treatment.